Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings

Endoscopy

Volumn 47, Issue 8, 2015, Pages 726-734

  Iacucci, Marietta ^a,c   Fort Gasia, Miriam ^a   Hassan, Cesare ^b   Panaccione, Remo ^a   Kaplan, Gilaad G ^a   Ghosh, Subrata ^a   Gui, Xianyong ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Nuova Regina Margherita ^*  (Italy)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MESALAZINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; COHORT ANALYSIS; COLONOSCOPE; COLONOSCOPY; COMPARATIVE STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SUBSCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCER HEALING; ULCERATIVE COLITIS; WHITE LIGHT ENDOSCOPY; BIOPSY; COLON; FOLLOW UP; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84938286311     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0034-1391863     Document Type: Article

References (42)

1. Travis S. P., Higgins P. D., Orchard T. et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther: 2011; 34 113 124
2. Carbonnel F., Lavergne A., Lemann M. et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci: 1994; 39 1550 1557
3. Korelitz B. I. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis: 2010; 16 1628 1630
4. Barreiro-de Acosta M., Lorenzo A., Mera J. et al. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis: 2009; 3 271 276
5. Baert F., Moortgat L., Van Assche G. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology: 2010; 138 463 468
6. Colombel J. F., Rutgeerts P., Reinisch W. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology: 2011; 141 1194 1201
7. Rutgeerts P., Van Assche G., Sandborn W. J. et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology: 2012; 142 1102 1111
8. Levy L. C., Siegel C. A. Endoscopic mucosal healing in ulcerative colitis. Aliment Pharmacol Ther: 2011; 33 1254 1255
9. Romkens T. E., Kampschreur M. T., Drenth J. P. et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis: 2012; 18 2190 2198
10. Sandborn W. J., Hanauer S., Van Assche G. et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis: 2014; 8 927 935
11. Kiesslich R., Goetz M., Hoffman A. et al. New imaging techniques and opportunities in endoscopy. Nat Rev Gastroenterol Hepatol: 2011; 8 547 553
12. Iacucci M., Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol: 2011; 4 129 143
13. Sauk J., Hoffman A., Anandasabapathy S. et al. High-definition and filter-aided colonoscopy. Gastroenterol Clinics North Am: 2010; 39 859 881
14. Kodashima S., Fujishiro M. Novel image-enhanced endoscopy with i-scan technology. World J Gastroenterol: 2010; 16 1043 1049
15. Atkinson M., Chak A. I-Scan: chromoendoscopy without the hassle? Dig Liver Dis: 2010; 42 18 19
16. Silverberg M. S., Satsangi J., Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol: 2005; Suppl A 19 5A 36A
17. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New Engl J Med: 1987; 317 1625 1629
18. Travis S. P., Schnell D., Krzeski P. et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology: 2013; 145 987 995
19. Kudo T., Matsumoto T., Esaki M. et al. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. Int J Colorectal Dis: 2009; 24 495 501
20. Esaki M., Kubokura N., Kudo T. et al. Endoscopic findings under narrow band imaging colonoscopy in ulcerative colitis. Dig Endosc: 2011; 23 140 142
21. Hefti M. M., Chessin D. B., Harpaz N. H. et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum: 2009; 52 193 197
22. Neumann H., Vieth M., Gunther C. et al. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis: 2013; 19 1935 1942
23. Rutgeerts P., Diamond R. H., Bala M. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc: 2006; 63 433 442
24. Colombel J. F., Sandborn W. J., Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New Engl J Med: 2010; 362 1383 1395
25. D'Haens G., Baert F., van Assche G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet: 2008; 371 660 667
26. D'Haens G. R. Top-down therapy for IBD: rationale and requisite evidence. Nature Rev Gastroenterol Hepatol: 2010; 7 86 92
27. Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol: 2011; 4 375 389
28. Sandborn W. J. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol: 2012; 8 117 119
29. Rutgeerts P., Sandborn W. J., Feagan B. G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl J Med: 2005; 353 2462 2476
30. Sandborn W. J., Colombel J. F., D'Haens G. et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther: 2013; 37 204 213
31. Froslie K. F., Jahnsen J., Moum B. A. et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology: 2007; 133 412 422
32. Ardizzone S., Maconi G., Russo A. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut: 2006; 55 47 53
33. Ferrante M., Vermeire S., Fidder H. et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis: 2008; 2 219 225
34. Rutter M., Saunders B., Wilkinson K. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology: 2004; 126 451 459
35. Ullman T. A., Itzkowitz S. H. Intestinal inflammation and cancer. Gastroenterology: 2011; 140 1807 1816
36. Allez M., Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol: 2010; 16 2626 2632
37. Moskowitz R. L., Shepherd N. A., Nicholls R. J. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis: 1986; 1 167 174
38. Gomes P., du Boulay C., Smith C. L. et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut: 1986; 27 92 95
39. Geboes K., Riddell R., Ost A. et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut: 2000; 47 404 409
40. Saverymuttu S. H., Camilleri M., Rees H. et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology: 1986; 90 1121 1128
41. Odze R., Antonioli D., Peppercorn M. et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol: 1993; 17 869 875
42. D'Haens G. R., Geboes K., Peeters M. et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology: 1998; 114 262 267